Report of Foreign Issuer (6-k)
June 19 2018 - 7:09AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of June 2018
001-36203
(Commission
File Number)
CAN-FITE
BIOPHARMA LTD.
(Exact
name of Registrant as specified in its charter)
10
Bareket Street
Kiryat
Matalon, P.O. Box 7537
Petach-Tikva
4951778, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or
Form 40-F.
Form 20-F
þ
Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
____
The
first four paragraphs and “Forward Looking Statements” of the press release attached to this Form 6-K are hereby incorporated
by reference into the registrant’s Registration Statements on Form F-3 (File Nos. 333-195124, 333-204795, 333-209037 and
333-220644), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or
reports subsequently filed or furnished.
On
June 19, 2018, Can-Fite BioPharma Ltd. (the “Company”) issued a press release providing an update on the Company’s
Phase II clinical trial of its drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose
disease has progressed on sorafenib therapy. A copy of this press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Can-Fite BioPharma Ltd.
|
|
|
|
Date: June 19, 2018
|
By:
|
/s/
Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024